Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells - PubMed (original) (raw)
Comparative Study
. 2005 Oct 3;202(7):907-12.
doi: 10.1084/jem.20050732.
Steven E Finkelstein, Christopher A Klebanoff, Paul A Antony, Douglas C Palmer, Paul J Spiess, Leroy N Hwang, Zhiya Yu, Claudia Wrzesinski, David M Heimann, Charles D Surh, Steven A Rosenberg, Nicholas P Restifo
Affiliations
- PMID: 16203864
- PMCID: PMC1397916
- DOI: 10.1084/jem.20050732
Comparative Study
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
Luca Gattinoni et al. J Exp Med. 2005.
Abstract
Depletion of immune elements before adoptive cell transfer (ACT) can dramatically improve the antitumor efficacy of transferred CD8+ T cells, but the specific mechanisms that contribute to this enhanced immunity remain poorly defined. Elimination of CD4+CD25+ regulatory T (T reg) cells has been proposed as a key mechanism by which lymphodepletion augments ACT-based immunotherapy. We found that even in the genetic absence of T reg cells, a nonmyeloablative regimen substantially augmented CD8+ T cell reactivity to self-tissue and tumor. Surprisingly, enhanced antitumor efficacy and autoimmunity was caused by increased function rather than increased numbers of tumor-reactive T cells, as would be expected by homeostatic mechanisms. The gammaC cytokines IL-7 and IL-15 were required for augmenting T cell functionality and antitumor activity. Removal of gammaC cytokine-responsive endogenous cells using antibody or genetic means resulted in the enhanced antitumor responses similar to those seen after nonmyeloablative conditioning. These data indicate that lymphodepletion removes endogenous cellular elements that act as sinks for cytokines that are capable of augmenting the activity of self/tumor-reactive CD8+ T cells. Thus, the restricted availability of homeostatic cytokines can be a contributing factor to peripheral tolerance, as well as a limiting resource for the effectiveness of tumor-specific T cells.
Figures
Figure 1.
Lymphodepletion enhances antitumor efficacy of adoptively transferred CD8**+** T cells. (a) 5 Gy TBI induces severe lymphopenia. Mice were treated with 5 Gy TBI or a nonmyeloablative chemotherapy regimen with 250 mg/kg Cytoxan + 50 mg/kg fludarabine. Absolute lymphocyte count was determined at the indicated time points. (b) Lymphodepletion augments antitumor responses. TBI or nonirradiated WT mice bearing 12-d-old established s.c. B16 tumors were left untreated or received adoptive transfer of 106 cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and rhIL-2. Data shown are representative of multiple independent experiments. Values represent the mean ± SEM. (c–e) Lymphodepletion does not result in increased numbers of adoptively transferred T cells. Absolute numbers of adoptively transferred pmel-1 cells (CD8+Thy1.1+) in the spleens (c) and in the blood (d) of tumor-bearing, TBI, and nonirradiated mice. Percentages of adoptively transferred pmel-1 cells (CD8+Thy1.1+) in the tumor (e) under conditions specified. (f–i). Lymphodepletion enhances effector functions of adoptively transferred T cells. 6 d after adoptive transfer, pmel-1 thy1.1+ cells were isolated from the spleens of irradiated and nonirradiated mice and co-cultured with irradiated splenocytes pulsed with the indicated doses of hgp10025–33. Unpulsed splenocytes were used as controls. Data shown are representative of two independent experiments.
Figure 2.
Even in the absence of T reg cells, ablation enhances antitumor efficacy of adoptively transferred T cells. (a) Ablation augments tumor responses in Rag1−/− mice. TBI or nonirradiated Rag1−/− mice bearing 14-d-old established s.c. B16 tumors were left untreated or received adoptive transfer of 106 cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and rhIL-2. Values represent the mean ± SEM. (b) Ablation augments tumor responses in MHC class II−/− mice. TBI or nonirradiated MHC class II−/− mice bearing 14-d-old established s.c. B16 tumors were left untreated or received adoptive transfer of 106 cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and rhIL-2. Values represent the mean ± SEM. (c) Ablation of mice genetically devoid of T reg cells augments autoimmunity. 30 d after treatment, mice were evaluated in a blinded fashion for the development of vitiligo. The percentages of mice with vitiligo are shown.
Figure 3.
Removal of NK cells enhances antitumor efficacy of adoptively transferred T cells. (a) Irradiation or administration of NK1.1 antibody efficiently depletes NK cells. Absolute numbers of NK1.1+ cells in the blood of tumor-bearing TBI Rag-1−/− mice and nonirradiated Rag-1−/− mice treated with NK1.1 antibody or Ig2aK antibody. Results are shown 3 d after the administration of 106 cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and rhIL-2. Values represent the mean ± SEM. (b) Removal of NK cells by antibody or by irradiation enhances antitumor efficacy of adoptively transferred T cells. Rag-1−/− mice bearing 9-d-old established s.c. B16 tumors received TBI or antibodies (anti-NK1.1 or Ig2aK antibody). Mice then received adoptive transfer of 106 cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and rhIL-2 or were left untreated. Values represent the mean ± SEM. (c) The genetic depletion of T cells, B cells, and NK cells recapitulates the effect of TBI. Rag-2−/−/γC −/− mice bearing 8-d-old established s.c. B16 tumors were either left untreated or received TBI. Where designated, mice received adoptive transfer of 106 cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and rhIL-2. Irradiation improved antitumor responses in control WT mice (not depicted). Values represent the mean ± SEM.
Figure 4.
Increased access to supportive endogenous cytokines into irradiated hosts enhances antitumor efficacy of transferred T cells. (a and b) Treatment is impaired in irradiated mice genetically deficient in IL-15 or IL-7 and IL-15 versus WT mice. WT, IL-15−/−, or IL-7−/−IL-15−/− mice bearing 9-d-old established s.c. B16 tumors were left untreated or received adoptive transfer of 106 cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and rhIL-2 with or without TBI. Values represent the mean ± SEM. (c and d) Absence of both IL-7 and IL-15 impaired proliferative responses of adoptively transferred T cells. Absolute numbers of adoptively transferred pmel-1 cells (CD8+Thy1.1+) in the spleens of tumor-bearing, nonirradiated WT, IL-15−/−, or IL-7−/−IL-15−/− mice (c). Absolute numbers of adoptively transferred pmel-1 cells (CD8+Thy1.1+) in the spleens of tumor-bearing, irradiated WT, IL-15−/−, or IL-7−/−IL-15−/− mice (d). (e–h) Increased access to IL-7 and IL-15 enhances effector functions of adoptively transferred T cells. 6 d after adoptive transfer pmel-1 thy1.1+ cells were isolated from the spleens of TBI WT, IL-15−/−, or IL-7−/−IL-15−/− mice and co-cultured with irradiated splenocytes pulsed with the indicated doses of hgp10025–33. Unpulsed splenocytes were used as controls. Because of the limited numbers of cells isolated from IL-7−/−IL-15−/− mice, pmel-1 cells were tested only against 1 μg/ml of peptide and unpulsed control.
Similar articles
- Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.
Johnson CB, May BR, Riesenberg BP, Suriano S, Mehrotra S, Garrett-Mayer E, Salem ML, Jeng EK, Wong HC, Paulos CM, Wrangle JM, Cole DJ, Rubinstein MP. Johnson CB, et al. Cancer Res. 2018 Jun 1;78(11):3067-3074. doi: 10.1158/0008-5472.CAN-17-2153. Epub 2018 Apr 10. Cancer Res. 2018. PMID: 29636345 Free PMC article. - Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Paulos CM, et al. J Clin Invest. 2007 Aug;117(8):2197-204. doi: 10.1172/JCI32205. J Clin Invest. 2007. PMID: 17657310 Free PMC article. - Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Wrzesinski C, et al. J Immunother. 2010 Jan;33(1):1-7. doi: 10.1097/CJI.0b013e3181b88ffc. J Immunother. 2010. PMID: 19952961 Free PMC article. - Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies.
Watanabe S, Arita M, Takahashi M, Saida Y, Koya T, Kikuchi T. Watanabe S, et al. Crit Rev Immunol. 2017;37(1):59-73. doi: 10.1615/CritRevImmunol.2018019497. Crit Rev Immunol. 2017. PMID: 29431079 Review. - Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer.
Ramanathan S, Gagnon J, Ilangumaran S. Ramanathan S, et al. Arch Immunol Ther Exp (Warsz). 2008 Sep-Oct;56(5):311-23. doi: 10.1007/s00005-008-0033-2. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18836862 Review.
Cited by
- Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.
Ahmed EN, Cutmore LC, Marshall JF. Ahmed EN, et al. Cancers (Basel). 2024 Sep 18;16(18):3186. doi: 10.3390/cancers16183186. Cancers (Basel). 2024. PMID: 39335157 Free PMC article. Review. - Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.
Mao C, Poimenidou M, Craig BT. Mao C, et al. Cancers (Basel). 2024 Aug 17;16(16):2865. doi: 10.3390/cancers16162865. Cancers (Basel). 2024. PMID: 39199637 Free PMC article. Review. - Strategies for Improving CAR T Cell Persistence in Solid Tumors.
Wittling MC, Cole AC, Brammer B, Diatikar KG, Schmitt NC, Paulos CM. Wittling MC, et al. Cancers (Basel). 2024 Aug 16;16(16):2858. doi: 10.3390/cancers16162858. Cancers (Basel). 2024. PMID: 39199630 Free PMC article. Review. - IL-2 based cancer immunotherapies: an evolving paradigm.
Rokade S, Damani AM, Oft M, Emmerich J. Rokade S, et al. Front Immunol. 2024 Jul 24;15:1433989. doi: 10.3389/fimmu.2024.1433989. eCollection 2024. Front Immunol. 2024. PMID: 39114660 Free PMC article. Review. - CAR-T and other adoptive cell therapies for B cell malignancies.
Lu P, Hill HA, Navsaria LJ, Wang ML. Lu P, et al. J Natl Cancer Cent. 2021 Jul 10;1(3):88-96. doi: 10.1016/j.jncc.2021.07.001. eCollection 2021 Sep. J Natl Cancer Cent. 2021. PMID: 39036373 Free PMC article. Review.
References
- Rosen, S.D. 2004. Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 22:129–156. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials